YamatoGast治疗消化不良症状。一项在德国常规实践中对日本Kampo Medicine注册的传统草药Rikkunshito提取物产品的非干预性研究。

IF 1.4 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY
Zeitschrift fur Gastroenterologie Pub Date : 2024-06-01 Epub Date: 2023-10-05 DOI:10.1055/a-2164-4534
Heidrun Reißenweber-Hewel, Christian Pehl, Silke Cameron, Jörn Thomsen, Kristina Röschmann-Doose
{"title":"YamatoGast治疗消化不良症状。一项在德国常规实践中对日本Kampo Medicine注册的传统草药Rikkunshito提取物产品的非干预性研究。","authors":"Heidrun Reißenweber-Hewel, Christian Pehl, Silke Cameron, Jörn Thomsen, Kristina Röschmann-Doose","doi":"10.1055/a-2164-4534","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dyspeptic symptoms belong to the most frequent reasons to seek medical advice and are a burden both for the individual affected and the healthcare system. In Japan, the traditional herbal Kampo prescription <i>rikkunshito</i> has proven benefit for this indication.</p><p><strong>Methods: </strong>In a prospective, multicentre, non-interventional study (NIS), the effectiveness, safety, and tolerability of a two-week treatment with the registered <i>rikkunshito</i> extract product <i>YamatoGast</i> was assessed in German patients with an acute episode of dyspeptic symptoms of functional origin under real-world conditions. The primary endpoint was the responsiveness to treatment assessed by the overall treatment effect (OTE) score. Secondary endpoints were the change in severity of dyspeptic symptoms and the change in quality of life (QoL). Safety evaluation was based on reported adverse drug reactions, drug compliance, and ratings of tolerability by physicians and patients.</p><p><strong>Results: </strong>Sixty-six patients were enrolled (mean age 48.9 years, 74% females). The treatment was well tolerated and highly beneficial, as expressed by pronounced responder rates of 78.9% for the primary endpoint OTE. All secondary endpoints were also met. The severity of dyspeptic symptoms significantly improved by 62-77% compared to baseline, confirmed by a remarkable improvement of QoL. Significant symptom relief started from the third day of treatment onwards.</p><p><strong>Conclusion: </strong>In this non-interventional study, two-week treatment with <i>YamatoGast</i> resulted in a significant improvement of dyspeptic symptoms and was associated with high patient response and satisfaction. <i>YamatoGast</i> was confirmed as a safe and clinically relevant therapeutic option for patients suffering upper gastrointestinal complaints in routine practice.</p>","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of dyspeptic symptoms with YamatoGast. A non-interventional study of a registered traditional herbal Rikkunshito extract product from Japanese Kampo Medicine in routine practice in Germany.\",\"authors\":\"Heidrun Reißenweber-Hewel, Christian Pehl, Silke Cameron, Jörn Thomsen, Kristina Röschmann-Doose\",\"doi\":\"10.1055/a-2164-4534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dyspeptic symptoms belong to the most frequent reasons to seek medical advice and are a burden both for the individual affected and the healthcare system. In Japan, the traditional herbal Kampo prescription <i>rikkunshito</i> has proven benefit for this indication.</p><p><strong>Methods: </strong>In a prospective, multicentre, non-interventional study (NIS), the effectiveness, safety, and tolerability of a two-week treatment with the registered <i>rikkunshito</i> extract product <i>YamatoGast</i> was assessed in German patients with an acute episode of dyspeptic symptoms of functional origin under real-world conditions. The primary endpoint was the responsiveness to treatment assessed by the overall treatment effect (OTE) score. Secondary endpoints were the change in severity of dyspeptic symptoms and the change in quality of life (QoL). Safety evaluation was based on reported adverse drug reactions, drug compliance, and ratings of tolerability by physicians and patients.</p><p><strong>Results: </strong>Sixty-six patients were enrolled (mean age 48.9 years, 74% females). The treatment was well tolerated and highly beneficial, as expressed by pronounced responder rates of 78.9% for the primary endpoint OTE. All secondary endpoints were also met. The severity of dyspeptic symptoms significantly improved by 62-77% compared to baseline, confirmed by a remarkable improvement of QoL. Significant symptom relief started from the third day of treatment onwards.</p><p><strong>Conclusion: </strong>In this non-interventional study, two-week treatment with <i>YamatoGast</i> resulted in a significant improvement of dyspeptic symptoms and was associated with high patient response and satisfaction. <i>YamatoGast</i> was confirmed as a safe and clinically relevant therapeutic option for patients suffering upper gastrointestinal complaints in routine practice.</p>\",\"PeriodicalId\":23853,\"journal\":{\"name\":\"Zeitschrift fur Gastroenterologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zeitschrift fur Gastroenterologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2164-4534\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur Gastroenterologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2164-4534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

引言:消化不良症状是寻求医疗建议的最常见原因,也是受影响个人和医疗系统的负担。在日本,传统草药Kampo处方rikkunshito已被证明对这种适应症有益。方法:在一项前瞻性、多中心、非介入性研究(NIS)中,对在现实世界条件下出现功能性消化不良症状急性发作的德国患者使用注册的rikkunshito提取物YamatoGast进行为期两周的治疗的有效性、安全性和耐受性进行了评估。主要终点是通过总体治疗效果(OTE)评分评估的对治疗的反应性。次要终点是消化不良症状严重程度的变化和生活质量(QoL)的变化。安全性评估基于医生和患者报告的药物不良反应、药物依从性和耐受性评级。结果:66名患者入选(平均年龄48.9岁,74%为女性)。该治疗具有良好的耐受性和高度有益性,主要终点OTE的显著应答率为78.9%。所有次要终点也得到满足。与基线相比,消化不良症状的严重程度显著改善了62-77%,生活质量显著改善证实了这一点。从治疗的第三天开始症状明显缓解。结论:在这项非介入性研究中,YamatoGast治疗两周可显著改善消化不良症状,并具有较高的患者反应和满意度。YamatoGast被证实是一种安全且临床相关的治疗方案,适用于常规实践中出现上消化道疾病的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of dyspeptic symptoms with YamatoGast. A non-interventional study of a registered traditional herbal Rikkunshito extract product from Japanese Kampo Medicine in routine practice in Germany.

Introduction: Dyspeptic symptoms belong to the most frequent reasons to seek medical advice and are a burden both for the individual affected and the healthcare system. In Japan, the traditional herbal Kampo prescription rikkunshito has proven benefit for this indication.

Methods: In a prospective, multicentre, non-interventional study (NIS), the effectiveness, safety, and tolerability of a two-week treatment with the registered rikkunshito extract product YamatoGast was assessed in German patients with an acute episode of dyspeptic symptoms of functional origin under real-world conditions. The primary endpoint was the responsiveness to treatment assessed by the overall treatment effect (OTE) score. Secondary endpoints were the change in severity of dyspeptic symptoms and the change in quality of life (QoL). Safety evaluation was based on reported adverse drug reactions, drug compliance, and ratings of tolerability by physicians and patients.

Results: Sixty-six patients were enrolled (mean age 48.9 years, 74% females). The treatment was well tolerated and highly beneficial, as expressed by pronounced responder rates of 78.9% for the primary endpoint OTE. All secondary endpoints were also met. The severity of dyspeptic symptoms significantly improved by 62-77% compared to baseline, confirmed by a remarkable improvement of QoL. Significant symptom relief started from the third day of treatment onwards.

Conclusion: In this non-interventional study, two-week treatment with YamatoGast resulted in a significant improvement of dyspeptic symptoms and was associated with high patient response and satisfaction. YamatoGast was confirmed as a safe and clinically relevant therapeutic option for patients suffering upper gastrointestinal complaints in routine practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Zeitschrift fur Gastroenterologie
Zeitschrift fur Gastroenterologie 医学-胃肠肝病学
CiteScore
1.40
自引率
15.40%
发文量
562
审稿时长
6-12 weeks
期刊介绍: Die Zeitschrift für Gastroenterologie ist seit über 50 Jahren die führende deutsche Fachzeitschrift auf dem Gebiet der Gastroenterologie. Sie richtet sich an Gastroenterologen und alle anderen gastroenterologisch interessierten Ärzte. Als offizielles Organ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten sowie der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie informiert sie zuverlässig und aktuell über die wichtigen Neuerungen und Entwicklungen in der Gastroenterologie.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信